Search

Search Constraints

You searched for: Author/Creator Vey, Norbert

Search Results

1. 316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A. (10th December 2020)

2. A case of platelet transfusion refractoriness in a CD36‐negative patient with acute myeloid leukemia: Diagnostic and therapeutic management. Issue 10 (10th October 2022)

3. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. Issue 1 (January 2014)

4. A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies. (7th May 2013)

5. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Issue 9 (September 2014)

6. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. (19th April 2022)

7. Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies. Issue 12 (18th March 2016)

8. Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies. (15th December 2016)

9. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. (7th March 2013)